OTLK

Outlook Therapeutics, Inc.

0.43 USD
+0.01 (+1.96%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Outlook Therapeutics, Inc. stock is down -3.14% since 30 days ago. The next earnings date is May 13, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 7 February’s closed higher than January. 100% of analysts rate it a buy.

About Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc. focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

  • Chardan Capital
    Thu Feb 15, 07:26
    buy
    upgrade
  • Guggenheim
    Thu Jan 25, 09:05
    buy
    upgrade
  • Brookline Capital
    Thu Jan 25, 05:39
    buy
    upgrade